Ovarian Cancer Clinical Trials (as of August 3, 2021)

 

ENGOT-ov67/AGO-OVAR 2.39

Leading group: AGO

Clinical Trial Study: Uplifted expansion cohort in ovarian cancer patient of the open label Phase Ib/II, first-in-human, dose escalation and expansion study of XMT-1536 in patietns with solid tumors likely to express NaPi2

Planned number of patients: 180

Participating groups:

BGOG, CEEGOG, GEICO, GINECO, MITO, NCRI, NOGGO, NSGO, PGOG

 

ENGOT-ov66/GEICO

Leading group: GEICO

Clinical Trial Study: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Planned number of patients: 150

Participating groups:

TBA

Planned start in September 2021

 

ENGOT-ov65/MaNGO

Leading group: MaNGO

Clinical Trial Study: TBA

Planned number of patients: 616

Participating groups:

GINECO, BGOG, NSGO, NOGGO, ISGO, PGOG, NCRI-UK, TRSGO, DGOG

Planned start in 4Q 2021

 

ENGOT-ov64/NSGO-CTU/SOLERO

Leading group: NSGO-CTU

Clinical Trial Study: An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer

Planned number of patients: 105

Participating groups:

CEEGOG, BGOG, GEICO, Swiss-GO

Planned start in 4Q 2021

 

ENGOT-ov63/GINECO/NIRVANA

Leading group: GINECO

Clinical Trial Study: NIRVANA (NIRaparib with or without beVacizumab in mAintenance after complete cytoreductioN in patients with ovArian cancer)

Planned number of patients: 390

Participating groups:

BGOG, MaNGO, DGOG,GEICO

Planned start in 4Q 2021

 

ENGOT-ov62/NOGGO/N-PLUS

Leading group: NOGGO

Clinical Trial Study: NiraParib in optimaLly debUlked ovarian cancer patientS

Planned number of patients: 536

Participating groups:

TBA

Planned start in 3Q 2021

 

ENGOT-ov61/GEICO/EPIK-O

Leading group: GEICO

Clinical Trial Study: EPIK-O: A Phase III, multi-center, randomized (1:1), openlabel, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

Planned number of patients: 358

Participating groups:

GINECO, NSGO, NCRI, CEEGOG, AGO, A-AGO, MITO, MaNGO and BGOG

 

ENGOT-ov60/NCRI

Leading group: NCRI 

Clinical Trial Study: A phase II trial of VS-6766 monotherapy and in combination with Defactinib in recurrent Low Grade Serous Ovarian Cancer

Planned number of patients: 116

Participating groups:

NCRI GOG partners, GEICO, BGOG, GINECO, MaNGO, Princess Margaret Consortium Canada

Planned start in 3Q 2021

 

ENGOT-ov59/NOGGO/MAMOC

Leading group: NOGGO 

Clinical Trial Study: Rucaparib MAintenance after Bevacizumab Maintenance following Carboplatin based first line chemotherapy in Ovarian Cancer patients

Planned number of patients: 190

Participating groups:

AGO

 

ENGOT-ov58/GINECO/TEDOVA

Leading group: GINECO 

Clinical trial Study: Neoepitope vaccine (TEDOPI) in combination with pembolizumab as maintenance treatment for ovarian cancer in platinum sensitive relapse

Planned number of patients: 160

Participating groups:

AGO, BGOG

Planned start in 3Q 2021

 

ENGOT-ov57/AGO

Leading group: AGO 

Clinical Trial Study: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemother-apy in advanced ovarian cancer

Planned number of patients: 970

Participating groups:

TBA

Planned start in Q3 2021

 

ENGOT-ov56/NSGO-CTU/DOVACC

Leading group: NSGO-CTU

Clinical Trial Study: A three-arm randomized study of olaparib, durvalumab and UV1 as maintenance therapy in BRCAwt patients in with relapsed ovarian cancer where platatinum combination therapy is an option

Planned number of patients: 184

Participating groups:

BGOG, NOGGO, HeCOG, DGOG, A-AGO

Planned start in Q3 2021

 

ENGOT-ov55/BGOG/MIRASOL

Leading group: BGOG 

Clinical trial Study: MIRASOL: A phase 3 registration trial for Mirvetuximab-Soravtansine using PS2+ scoring in FRα high platinum resistant ovarian cancer patients

Planned number of patients: 430

Participating groups:

GEICO, DGOG, CEEGOG, ISGO, PGOG, MANGO, NCRI, AGO, GINECO

 

ENGOT-ov54/Swiss-GO/MATAO

Leading group: Swiss-GO 

Clinical Trial Study: MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a Randomized Double-blinded Placebo-controlled Phase III Trial

Planned number of patients: 540

Participating groups:

AGO, A-AGO

Planned start in 4Q 2020

 

ENGOT-ov53/CEEGOG/Vitalia

Leading group: CEEGOG

Clinical Trial Study: A phase III, multicenter, randomized, double-blind, placebo-controlled add-on trial of DCVAC/OvCa added to second-line chemotherapy with or without bevacizumab in the induction period, followed by DCVAC/OvCa with either bevacizumab, PARP inhibitor or best supportive care in maintenance period in patients with first relapse of platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma

Planned number of patients: 754

Participating groups:

AGO-A, BGOG, DGOG, GEICO, NOGGO (including AGO sites), NSGO, PGOG, ManGo, MITO, SGCTG (including NCRI/MRC sites)

Planned start in 3Q 2021

 

ENGOT-ov52/DGOG/OVHIPEC-2

Leading group: DGOG

Clinical Trial Study: OVHIPEC-2 Randomized phase 3 trial comparing primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for stage III epithelial ovarian cancer

Planned number of patients: 538

Participating groups:

Cancer trials Ireland, ANZGOG, NSGO-CTU, MITO, GINECO, NCRI, USA (as guest member of the DGOG)

 

ENGOT-ov51/MITO/NItCHE

Leading group: MITO

Clinical Trial Study: Randomized phase III trial on Niraparib-TSR 042 vs TSR 042 vs physician's choice chemotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for further platinum treatment

Planned number of patients: 427

Participating groups:

MaNGO, GINECO, HeCOG, CEEGOG, NOGGO

Planned start in 3Q 2020

 

ENGOT-ov50/BGOG/INNOVATE-3

Leading group: BGOG

Clinical Trial Study: INNOVATE-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC)

Planned number of patients: 540

Participating groups:

GEICO, SAKK, MITO, MANGO, PGOG, NOGGO, CEEGOG, DGOG, ISGO, AGO

 

ENGOT-ov49/MaNGO/NEWTON

Leading group: MaNGO

Clinical Trial Study: A multicenter, open-label phase II trial of customized dosing (Rapid Adjustment of Dose to reduce Adverse Reactions “RADAR” dosing) of niraparib as maintenance therapy in platinum sensitive ovarian, fallopian tube or primary peritoneal recurrent cancer patients.

Planned number of patients: 105

Participating groups:

NOGGO

 

ENGOT-ov47-TR /NOGGO-AGO TR2/HELPER

Leading group: NOGGO

Clinical Trial Study: Prospective study of HE4 serum level in patients with first platinum sensitive relapsed ovarian cancer

Planned number of patients: 500

Participating groups:

A-AGO, AGO, BGOG, GEICO, MaNGO, MITO, NCRI

 

ENGOT-ov46/AGO/DUO-O

Leading group: AGO

Clinical Trial Study: A phase III randomised, double-blind, placebo-controlled, multicentre study of Durvalumab in combination with chemotherapy and Bevacizumab, followed by maintenance Durvalumab, Bevacizumab and Olaparib in newly diagnosed advanced ovarian cancer patients (DUO-O)

Planned number of patients: 1259

Participating groups:

A-AGO, BGOG, GEICO, GINECO, MaNGO, MITO, NSGO, PGOG, TRSGO

 

ENGOT-ov45/NCRI/ATHENA

Leading group: NCRI

Clinical Trial Study: ATHENA - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

Planned number of patients: 1000

Participating groups:

AGO, BGOG, CEEGOG, CTI, GEICO, HeCOG, ISGO, MITO, NSGO, PGOG, TRSGO, (GOG Foundation Partners and other global groups)

 

ENGOT-ov41/GEICO/ANITA

Leading group: GEICO

Clinical Trial Study: ANITA (Atezolizumab and NIraparib Treatment Association in recurrent ovarian cancer): A randomized phase III trial of platinum-based chemotherapy followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 Months

Planned number of patients: 414

Participating groups:

AGO, BGOG, GINECO, ISGO, MaNGO

 

ENGOT-ov40/NOGGO/Expression VI

Leading group: NOGGO

Clinical Trial Study: Holistic Analysis of longterm survivors with ovarian cancer

Planned number of patients: 600

Participating groups:

A-AGO, BGOG, CEEGOG, GEICO, TRSGO, Swiss-GO, (Romania, PASGO)

 

ENGOT-ov35/NCRI/ICON 9

Leading group: NCRI

Clinical Trial Study: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Planned number of patients: 330

Participating groups:

SGCTG (ANZGOG, NCIC)

 

ENGOT-ov34/AGO Ovar 2.29

Leading group: AGO

Clinical Trial Study: Atezolizumab in combination with Bevacizumab +/- Chemotherapy versus Chemo-BEV standard in recurrent ovarian cancer – a randomised trial

Planned number of patients: 664

Participating groups: 

A-AGO, BGOG, GEICO, GINECO, NSGO, SAKK

 

ENGOT-ov33/AGO Ovar OP.7/TRUST

Leading group: AGO

Clinical Trial Study: TRUST-Trial on Radical Upfront Surgical Therapy

Planned number of patients: 772

Participating groups:

GINECO, MaNGO, NSGO, NOGGO

  

 

ENGOT-ov13/NCRI/ICON8 B

Leading group: NCRI

Clinical Trial Study: An international phase III randomised trial of dose fractionated chemotherapy compared to standard three weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer

Planned number of patients: 590

Participating groups:

Cancer Trials Ireland, CTU EOC (Swiss)